PlainPharmaWatch

CMS Open Payments · Program Year 2024

Perfuze Limited

Perfuze Limited reported $568,176.13 in payments to 6 physicians and teaching hospitals across 13 transactions.

See the rankings → How this is sourced
$568.2K
Total payments
13
Transactions
6
Recipients
+$13.4K
General Payments vs PY2023

Perfuze Limited reported $568,176.13 in payments to 6 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #733 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $94.7K per recipient across 2 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Perfuze Limited pairs above-median payment volume with a moderately concentrated payment pattern.

#733
of 1,925 companies
0.0%
of all US industry payments
0.5%
paid to its single top recipient
2
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Perfuze Limited's CMS-reported General Payments increased by $13.4K (+58.7%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2023: PERFUZE LIMITEDPY2024: Perfuze Limited. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$22.9KPY2024$36.4K
PY2023
$22,910.22
PY2024
$36,354.06

How Perfuze Limited ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Perfuze Limited's total vs. every reporting company

CMS Open Payments, Program Year 2024

$568,176 Top 38% higher than 62% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). This entry sits in this band. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Perfuze Limited

$568,176.13: that is what Perfuze Limited reported in payments to 6 physicians and teaching hospitals during Program Year 2024, spread across 13 transactions ($43.7K per transaction, $94.7K per recipient). The company sits at rank #733 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $18.9K across 4 transactions, 3.3% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Perfuze Limited's 2-category general-payment breakdown at $18.9K, 3.3% of the reported total.

How Perfuze Limited divides its payments

How the reported total splits across payment categories

1. Consulting Fee$18.9K2. Travel and Lodging$17.5K
Payment Type Amount Transactions
Consulting Fee $18.9K 4
Travel and Lodging $17.5K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $36,354.06 (100.0%) of $36,354.06 in this company's General Payments records across 5 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Perfuze Limited

The five named recipients with the highest reported General Payments from this company

Ameer Hassan$17.5KAdnan Qureshi$6.7KJose Suarez$5.0KSameer Ansari$4.7KDavid Fiorella$2.5K
  1. 1

    Ameer Hassan

    $17,498.81 across 2 reported transactions

  2. 2

    Adnan Qureshi

    $6,650.00 across 1 reported transactions

  3. 3

    Jose Suarez

    $5,040.05 across 1 reported transactions

  4. 4

    Sameer Ansari

    $4,665.20 across 1 reported transactions

  5. 5

    David Fiorella

    $2,500.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $43.7K. Average per recipient: $94.7K.

Total Amount

$568,176.13

Avg per Transaction

$43.7K

Avg per Recipient

$94.7K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Perfuze Limited Share

0.0%

#733 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Perfuze Limited

Hyperfine Operations, Inc.

$568.6K 56 recipients

Republic Spine

$567.3K 45 recipients

Expanding Innovations, Inc.

$566.5K 92 recipients

CTL Medical Corporation

$565.3K 315 recipients

Zest Holdings, LLC

$571.1K 1,385 recipients

Maxx Orthopedics, Inc.

$563.7K 215 recipients

Frequently Asked Questions

How much did Perfuze Limited pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $568,176.13 from Perfuze Limited to physicians and hospitals across 13 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Perfuze Limited? ▾
Averaging $94.7K per recipient, Perfuze Limited's 2024 payments reached 6 physicians and teaching hospitals.
What types of payments did Perfuze Limited make? ▾
Perfuze Limited made 2 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Consulting Fee" at $18.9K, representing 3.3% of the company's reported total.
How does Perfuze Limited rank among pharmaceutical companies? ▾
Perfuze Limited ranks #733 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Perfuze Limited? ▾
Perfuze Limited's 13 transactions to 6 recipients in 2024 averaged $43.7K per transaction.
Where does the payment data for Perfuze Limited come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Perfuze Limited's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.